Bullish Moving Averages
3
Bearish Moving Averages
13
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
2103.80Today’s High
2127.0052W low
1242.0052W High
2490.00Open Price
2109.00Prev. Close
2122.1000Volume
41100.00Value
86788815.00Fundamentals
Market Cap Cr
84600.10
Price to Earnings
44.10
Price to Book Value
8.80
Dividend Yield
0.00
PE to Growth
0.90
Op Revenue TTM Cr
10334.77
Net Profit TTM Cr
1920.21
Cash From Operating Activity Cr
2152.44
Return on Equity %
20.43
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
18 May, 2024
64.4
Week
54.1
Month
59.2
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
2114.13
PIVOT
First Resistance
2124.52
Second Resistance
2137.38
Third Resistance
2147.77
First Support
2101.27
Second Support
2090.88
Third Support
2078.02
Relative Strength Index
37.57
Money Flow Index
10.09
MACD
-46.35
MACD Signal
-22.82
Average True Range
89.06
Average Directional Index
19.58
Rate of Change (21)
-11.85
Rate of Change (125)
13.39
Commodity Channel Index
-119.5
Williams %R
-85.6
BETA
1 Month
-0.13
3 Month
0.68
1 Year
0.27
3 Year
PRICE CHANGE ANALYSIS
↓ -5.59%
1 Week
Low
High
2060
2299
↓ -7.43%
1 Month
Low
High
2060
2490
↓ -4.61%
3 Months
Low
High
2016.55
2490
↑ 9.98%
6 Months
Low
High
1821
2490
↑ 55.91%
1 Year
Low
High
1242
2490
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 2236.54 | 2425.80 | 2511.46 | 2357.65 | 1914.58 | 1968.64 | 2326.70 | 2080.03 | 1652.97 | |
| Operating Expenses Qtr | 1605.35 | 1755.46 | 1818.15 | 1760.74 | 1490.96 | 1562.73 | 1735.21 | 1640.87 | 1335.62 | |
| Operating Profit Qtr | 547.33 | 603.11 | 635.19 | 539.47 | 381.16 | 373.50 | 522.34 | 420.39 | 309.20 | |
| EBIDT Qtr Cr | 631.19 | 670.34 | 693.31 | 596.90 | 423.62 | 405.90 | 591.49 | 439.16 | 317.35 | |
| Depreciation Qtr | 82.29 | 89.73 | 77.04 | 68.54 | 67.30 | 71.02 | 66.04 | 65.22 | 36.41 | |
| Net Profit Qtr | 454.17 | 487.07 | 472.88 | 409.28 | 280.99 | 248.87 | 420.23 | 298.16 | 217.48 | |
| Basic EPS Qtr | 11.34 | 12.16 | 11.80 | 10.22 | 7.01 | 6.21 | 10.49 | 7.44 | 5.43 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 9531.45 | 8289.94 | 7419.77 | 5677.68 | 4888.26 | |
| Operating Expenses Annual Cr | 6939.70 | 6429.77 | 5457.42 | 4151.31 | 3550.96 | |
| Operating Profit Annual | 2325.10 | 1697.38 | 1799.61 | 1378.29 | 1243.46 | |
| Operating Profit Margin Annual % | 24.39 | 20.48 | 24.25 | 24.28 | 25.44 | |
| Total Expenses Annual Cr | 7271.88 | 6727.10 | 5622.23 | 4237.47 | 3623.34 | |
| EBIDT Annual Cr | 2591.74 | 1860.16 | 1962.34 | 1526.37 | 1337.31 | |
| EBIDT Annual margin % | 27.19 | 22.44 | 26.45 | 26.88 | 27.36 | |
| Depreciation | 317.61 | 269.58 | 120.98 | 78.19 | 61.77 | |
| PAT Before ExtraOrdinary Items Annual Cr | 1823.41 | 1248.26 | 1335.13 | 1084.37 | 958.23 | |
| Net Profit Annual | 1823.41 | 1248.26 | 1335.13 | 1084.37 | 958.23 | |
| Basic EPS Annual | 45.52 | 31.16 | 33.33 | 27.07 | 23.92 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 9623.81 | 7783.91 | 6068.77 | 4734.27 | 3651.45 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 200.54 | 168.12 | 116.06 | 67.15 | 63.89 | |
| Total Current Liabilities Annual Cr | 1593.36 | 1419.09 | 2228.01 | 1078.91 | 815.77 | |
| Total Capital Plus Liabilities Annual Cr | 11417.71 | 9371.12 | 8412.85 | 5880.33 | 4531.11 | |
| Fixed Assets Annual | 3591.92 | 3637.00 | 3273.08 | 1152.98 | 1092.39 | |
| Total Non Current Assets Annual | 5858.79 | 5854.21 | 5156.07 | 2790.35 | 2582.50 | |
| Total Current Assets Annual | 5558.92 | 3516.91 | 3256.78 | 3089.98 | 1948.60 | |
| Total Assets Annual | 11417.71 | 9371.12 | 8412.85 | 5880.33 | 4531.11 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 168.37 | 275.47 | 0.00 | 0.00 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 1982.97 | 1798.99 | 812.29 | 1022.33 | 959.61 | |
| Cash from Investing Activity Annual | -1919.12 | -1040.61 | -1369.34 | -1127.16 | -395.68 | |
| Cash from Financing Annual Activity | -8.68 | -710.41 | 578.92 | 88.87 | -558.91 | |
| Net Cash Flow Annual | - | 47.96 | 21.87 | -15.96 | 5.02 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 240.24 | 194.31 | 151.50 | 118.18 | 91.15 | |
| ROE Annual % | 18.94 | 16.03 | 22.00 | 22.90 | 26.24 | |
| ROCE Annual % | 23.14 | 20.00 | 29.77 | 30.16 | 34.33 | |
| Total Debt to Total Equity Annual | 0.00 | 0.00 | 0.11 | 0.02 | 0.00 | |
| EBDIT Annual Margin % | 27.97 | 22.88 | 27.04 | 27.60 | 27.89 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 2533.23 | 2677.09 | 2768.08 | 2637.24 | 2100.18 | 2128.07 | 2453.21 | 2196.54 | 1759.29 | |
| Operating Expenses Qtr | 1849.99 | 2000.45 | 2025.45 | 1923.80 | 1635.99 | 1653.89 | 1835.13 | 1723.79 | 1440.93 | |
| Operating Profit Qtr | 591.10 | 606.51 | 682.65 | 654.82 | 416.68 | 437.04 | 590.71 | 456.20 | 284.83 | |
| EBIDT Qtr Cr | 683.23 | 676.64 | 742.62 | 713.43 | 464.19 | 474.18 | 618.09 | 472.74 | 318.36 | |
| Depreciation Qtr | 104.69 | 109.73 | 96.48 | 87.35 | 84.52 | 84.79 | 78.59 | 78.02 | 47.36 | |
| Net Profit Qtr | 471.24 | 453.76 | 501.03 | 494.19 | 285.44 | 284.15 | 419.71 | 292.56 | 190.08 | |
| Basic EPS Qtr | 11.76 | 11.33 | 12.51 | 12.15 | 7.13 | 7.09 | 10.48 | 7.30 | 4.74 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 10615.63 | 8878.00 | 7977.58 | 6385.38 | 5975.65 | |
| Operating Expenses Annual Cr | 7799.70 | 6848.80 | 5792.20 | 4566.33 | 4428.42 | |
| Operating Profit Annual | 2535.07 | 1900.64 | 1989.35 | 1648.10 | 1436.81 | |
| Operating Profit Margin Annual % | 23.88 | 21.41 | 24.94 | 25.81 | 24.04 | |
| Total Expenses Annual Cr | 8231.49 | 7219.18 | 6017.43 | 4705.45 | 4549.45 | |
| EBIDT Annual Cr | 2815.93 | 2029.20 | 2185.38 | 1819.05 | 1547.23 | |
| EBIDT Annual margin % | 26.53 | 22.86 | 27.39 | 28.49 | 25.89 | |
| Depreciation | 398.25 | 325.92 | 166.62 | 118.97 | 99.06 | |
| PAT Before ExtraOrdinary Items Annual Cr | 1926.56 | 1297.25 | 1438.51 | 1281.36 | 1044.61 | |
| Net Profit Annual | 1912.90 | 1281.86 | 1433.47 | 1265.43 | 1030.42 | |
| Basic EPS Annual | 47.75 | 32.00 | 35.78 | 31.59 | 25.72 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 9363.09 | 7435.22 | 6155.23 | 4722.00 | 3485.31 | |
| Minority Interest Liability Annual Cr | 212.70 | 188.07 | 161.08 | 140.89 | 186.26 | |
| Total Non Current Liabilities Annual Cr | 267.74 | 229.02 | 207.96 | 156.34 | 143.13 | |
| Total Current Liabilities Annual Cr | 2119.73 | 1863.14 | 2623.47 | 1353.40 | 1258.59 | |
| Total Capital Plus Liabilities Annual Cr | 11963.25 | 9715.45 | 9147.74 | 6372.63 | 5073.28 | |
| Fixed Assets Annual | 4807.04 | 4780.78 | 4269.22 | 2015.95 | 1896.11 | |
| Total Non Current Assets Annual | 5313.04 | 5387.58 | 4740.92 | 2465.99 | 2251.07 | |
| Total Current Assets Annual | 6650.21 | 4327.87 | 4406.82 | 3906.64 | 2822.22 | |
| Total Assets Annual | 11963.25 | 9715.45 | 9147.74 | 6372.63 | 5073.28 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 167.78 | 211.93 | 183.16 | 88.52 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 2152.45 | 1813.30 | 919.78 | 1137.24 | 1069.70 | |
| Cash from Investing Activity Annual | -2081.69 | -1054.13 | -1369.14 | -1222.21 | -439.15 | |
| Cash from Financing Annual Activity | 5.27 | -739.73 | 604.62 | -7.81 | -530.74 | |
| Net Cash Flow Annual | - | 19.44 | 155.25 | -92.78 | 99.81 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 239.04 | 190.30 | 157.68 | 121.39 | 91.65 | |
| ROE Annual % | 20.43 | 17.24 | 23.28 | 26.79 | 29.56 | |
| ROCE Annual % | 24.56 | 21.69 | 30.94 | 33.87 | 37.96 | |
| Total Debt to Total Equity Annual | 0.02 | 0.02 | 0.14 | 0.05 | 0.04 | |
| EBDIT Annual Margin % | 27.24 | 23.19 | 28.08 | 29.27 | 26.37 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| ICICI PRUDENTIAL MUTUAL FUND | 1.6 | 73806612 | - | - |
| AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL FUND | 1.54 | 73806613 | - | - |
| SBI NIFTY MIDCAP 150 INDEX FUND | 1.52 | 73806614 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Sheetal Arora | 4.81 | 73806524 | 0 | 0 |
| Puja Juneja | 2.88 | 73806525 | 0 | 0 |
| Poonam Juneja | 2.64 | 73806526 | 0 | 0 |
| Arjun Juneja | 2.04 | 73806527 | 0 | 0 |
| Ramesh Juneja | 1.71 | 73806528 | 0 | 0 |
| Rajeev Juneja | 1.62 | 73806529 | 0 | 0 |
| Chanakya Juneja | 0.97 | 73806530 | 0 | 0 |
| Eklavya Juneja | 0.97 | 73806531 | 0 | 0 |
| Mishka Arora | 0.74 | 73806532 | 0 | 0 |
| Ramesh Juneja Family Trust (Held in the name of Ramesh Juneja, Managing Trustee) | 20.81 | 73806555 | 0 | 35.56 |
| Rajeev Juneja Family Trust (Held in the name of Rajeev Juneja, Managing Trustee) | 19.95 | 73806556 | 0 | 35.08 |
| Prem Sheetal Family Trust (Held in the name of Arora Family Private Limited, Trustee) | 15.42 | 73806557 | 0 | 36.33 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| ICICI PRUDENTIAL MUTUAL FUND | 1.6 | 73806612 |
| AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL FUND | 1.54 | 73806613 |
| SBI NIFTY MIDCAP 150 INDEX FUND | 1.52 | 73806614 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| HEMA CIPEF (I) LIMITED | 2.22 | 73806626 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 15, 2024 | Audited Results & Others | - |
| Jan 31, 2024 | Quarterly Results | - |
| Oct 31, 2023 | Quarterly Results | - |
| Aug 02, 2023 | Quarterly Results | - |
| May 30, 2023 | Audited Results | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
18 May 2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement of Postal Ballot Notice
17 May 2024
Mankind Pharma Ltd - 543904 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Postal Ballot Notice
17 May 2024
Mankind Pharma Q4 Results Review - Strong Performance From Formulation; Consumer Health Subdued: Dolat Capital
Export business shows exponential growth on low base and one-offs
16 May 2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Conference Call for Q4FY24 - Audio Recording
16 May 2024
Mankind Pharma looking at acquisitions, keeping funds ready for an opportunity, says management
The company has an enabling or blanket approval to be ready for a big or small acquisition
16 May 2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of consolidated audited financial results for the quarter and financial year ended on March 31, 2024.
16 May 2024
Mankind Pharma Results Earnings Call for Q4FY24
Conference Call with Mankind Pharma Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
16 May 2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Mankind Pharma Ltd.
Pharmaceuticals company Mankind Pharma announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from Operations at Rs 2,441 crore, up by 19% YoY Domestic revenue at Rs 2,174 crore, up 10% YoY; Exports at Rs 267 crore, up 230% YoY EBITDA margin of 24.3%, and PAT margin of 19.5% Diluted EPS of Rs 11.7, up by 65% YoY (FV Re.1) FY24 Financial Highlights: Revenue from Operations at Rs 10,335 crore, up by 18% Domestic revenue at Rs 9,522 crore, up by 13%; Exports at Rs 813 crore, up by 175% EBITDA margin of 24.7%, and PAT margin of 18.8% Diluted EPS of Rs 47.7, up by 49% (FV Re.1) Cash flow from operations of Rs 2,152 crore, up by 19% Net cash balance of Rs 3,260 crore as on 31st March 2024 Rajeev Juneja – Vice Chairman & Managing Director said, “This year, we have achieved a revenue milestone of Rs 10,000 crore. and added 3 more brand families worth over Rs 100 crore raising the total to 23. Our strong revenue growth of 18% with EBITDA and PAT margin of ~25% and ~19% respectively is supported by an increase in Chronic share to 36% and growth in Modern Trade of over 50%. We have further strengthened our chronic product portfolio with strategic in-house launches coupled with in-licensing of products like Symbicort – a globally renowned inhaler from Astra Zeneca. Multiple technology led business transformation projects implemented across functions to further enhance efficiency and productivity laying the foundation for our next phase of growth.” Result PDF
15 May 2024
Mankind Pharma Ltd - 543904 - Clarification On News Item Appearing In Www.Business-Standard.Com
Clarification on news item appearing in www.business-standard.com
15 May 2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and financial year ended 31st March 2024.
